Matches in SemOpenAlex for { <https://semopenalex.org/work/W2275487949> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2275487949 endingPage "7048" @default.
- W2275487949 startingPage "7048" @default.
- W2275487949 abstract "7048 Background c-Kit over-expression is found in multiple cancers including up to 70% of SCLC. STI571 can inhibit c-kit tyrosine kinase activity and has high efficacy in chemoresistant c-kit positive (c-kit+) gastrointestinal stromal tumors. A phase II study of STI571 in unselected SCLC pts by Johnson et al., was negative, but inconclusive for proof- of - principle purposes, since 80% of tumors did not express c-kit. We therefore sought to evaluate clinical activity of STI571 in the treatment of patients with recurrent and refractory c-kit+ SCLC. Methods Only c-kit+ SCLC cases were enrolled on this study (≥ 1+ by immunohistochemistry). Arm A included pts progressing < 3 months and Arm B included pts progressing ≥ 3 months after previous treatment. STI571 was administered at a dose of 400 mg bid continuously, with a cycle length of 28 days. A single stage Simon design with a planned interim analysis was used to evaluate the 16 week progression free rate in each arm. Results A total of 29 evaluable pts were entered into the study (7 arm A, median age 68; 22 arm B, median age 65). Median number of treatment cycles was 1 in both arms. All pts are now off active treatment. Grade3+ non-hematologic adverse events were seen in 15(52%) pts, with nausea, vomiting, dyspnea, fatigue, anorexia and dehydration occurring in at least 10% of pts. Median survival was 3.9 and 5.3 months and median time to progression was 1 and 1.1 month for arms A and B, respectively. Enrollment to arm A was temporarily suspended prior to reaching interim analysis due to progression (29%), early deaths (29%), and refusal (42%). No objective responses and no confirmed stable disease ≥ 6 weeks were seen in either arm. Accrual was permanently terminated to both arms as no patient was progression-free at 16 weeks. Conclusion STI571 was inactive in spite of pt selection for c-kit+ SCLC. Our results strengthen the collective evidence that prediction of efficacy of novel therapeutic agents based on target expression, rather than pathway activation (for example through activating mutations), may not be a valid paradigm for drug development. No significant financial relationships to disclose." @default.
- W2275487949 created "2016-06-24" @default.
- W2275487949 creator A5002528975 @default.
- W2275487949 creator A5010162250 @default.
- W2275487949 creator A5011536574 @default.
- W2275487949 creator A5025646273 @default.
- W2275487949 creator A5041114807 @default.
- W2275487949 creator A5058147268 @default.
- W2275487949 creator A5062848479 @default.
- W2275487949 creator A5066001765 @default.
- W2275487949 date "2005-06-01" @default.
- W2275487949 modified "2023-09-24" @default.
- W2275487949 title "A phase II NCCTG/CALGB trial of imatinib (STI571) in patients (pts) with c-kit-expressing relapsed small cell lung cancer (SCLC)" @default.
- W2275487949 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.7048" @default.
- W2275487949 hasPublicationYear "2005" @default.
- W2275487949 type Work @default.
- W2275487949 sameAs 2275487949 @default.
- W2275487949 citedByCount "4" @default.
- W2275487949 countsByYear W22754879492013 @default.
- W2275487949 crossrefType "journal-article" @default.
- W2275487949 hasAuthorship W2275487949A5002528975 @default.
- W2275487949 hasAuthorship W2275487949A5010162250 @default.
- W2275487949 hasAuthorship W2275487949A5011536574 @default.
- W2275487949 hasAuthorship W2275487949A5025646273 @default.
- W2275487949 hasAuthorship W2275487949A5041114807 @default.
- W2275487949 hasAuthorship W2275487949A5058147268 @default.
- W2275487949 hasAuthorship W2275487949A5062848479 @default.
- W2275487949 hasAuthorship W2275487949A5066001765 @default.
- W2275487949 hasConcept C121332964 @default.
- W2275487949 hasConcept C126322002 @default.
- W2275487949 hasConcept C141071460 @default.
- W2275487949 hasConcept C142424586 @default.
- W2275487949 hasConcept C143998085 @default.
- W2275487949 hasConcept C197934379 @default.
- W2275487949 hasConcept C2776694085 @default.
- W2275487949 hasConcept C2777583451 @default.
- W2275487949 hasConcept C2778375690 @default.
- W2275487949 hasConcept C2778729363 @default.
- W2275487949 hasConcept C2780580376 @default.
- W2275487949 hasConcept C2780852908 @default.
- W2275487949 hasConcept C3019892230 @default.
- W2275487949 hasConcept C31760486 @default.
- W2275487949 hasConcept C71924100 @default.
- W2275487949 hasConcept C87355193 @default.
- W2275487949 hasConcept C90924648 @default.
- W2275487949 hasConceptScore W2275487949C121332964 @default.
- W2275487949 hasConceptScore W2275487949C126322002 @default.
- W2275487949 hasConceptScore W2275487949C141071460 @default.
- W2275487949 hasConceptScore W2275487949C142424586 @default.
- W2275487949 hasConceptScore W2275487949C143998085 @default.
- W2275487949 hasConceptScore W2275487949C197934379 @default.
- W2275487949 hasConceptScore W2275487949C2776694085 @default.
- W2275487949 hasConceptScore W2275487949C2777583451 @default.
- W2275487949 hasConceptScore W2275487949C2778375690 @default.
- W2275487949 hasConceptScore W2275487949C2778729363 @default.
- W2275487949 hasConceptScore W2275487949C2780580376 @default.
- W2275487949 hasConceptScore W2275487949C2780852908 @default.
- W2275487949 hasConceptScore W2275487949C3019892230 @default.
- W2275487949 hasConceptScore W2275487949C31760486 @default.
- W2275487949 hasConceptScore W2275487949C71924100 @default.
- W2275487949 hasConceptScore W2275487949C87355193 @default.
- W2275487949 hasConceptScore W2275487949C90924648 @default.
- W2275487949 hasIssue "16_suppl" @default.
- W2275487949 hasLocation W22754879491 @default.
- W2275487949 hasOpenAccess W2275487949 @default.
- W2275487949 hasPrimaryLocation W22754879491 @default.
- W2275487949 hasRelatedWork W1509944323 @default.
- W2275487949 hasRelatedWork W1980324865 @default.
- W2275487949 hasRelatedWork W2068354996 @default.
- W2275487949 hasRelatedWork W2156337883 @default.
- W2275487949 hasRelatedWork W2369852829 @default.
- W2275487949 hasRelatedWork W2372442000 @default.
- W2275487949 hasRelatedWork W2378183542 @default.
- W2275487949 hasRelatedWork W2394317912 @default.
- W2275487949 hasRelatedWork W2415576058 @default.
- W2275487949 hasRelatedWork W2897258609 @default.
- W2275487949 hasVolume "23" @default.
- W2275487949 isParatext "false" @default.
- W2275487949 isRetracted "false" @default.
- W2275487949 magId "2275487949" @default.
- W2275487949 workType "article" @default.